SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-208702
Filing Date
2022-08-01
Accepted
2022-08-01 16:21:57
Documents
14
Period of Report
2022-08-01
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d332130d8k.htm   iXBRL 8-K 24600
2 EX-99.1 d332130dex991.htm EX-99.1 17295
6 GRAPHIC g332130g0801223226477.jpg GRAPHIC 5087
  Complete submission text file 0001193125-22-208702.txt   176952

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA aeri-20220801.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aeri-20220801_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aeri-20220801_pre.xml EX-101.PRE 11270
8 EXTRACTED XBRL INSTANCE DOCUMENT d332130d8k_htm.xml XML 3404
Mailing Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703
Business Address 4301 EMPEROR BOULEVARD SUITE 400 DURHAM NC 27703 (919) 237-5300
AERIE PHARMACEUTICALS INC (Filer) CIK: 0001337553 (see all company filings)

IRS No.: 203109565 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36152 | Film No.: 221125063
SIC: 2836 Biological Products, (No Diagnostic Substances)